OPM announces its 2025 annual results andprovides an update on its clinical developments

OPM announces its 2025 annual results and provides an update on its clinical developments

Dijon (France), April 30, 2026, at 6:00 p.m. CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2025 financial results, as approved by the Board of Directors on April 27, 2026.